06:30 AM EDT, 07/16/2025 (MT Newswires) -- Astrazeneca ( AZN ) said Wednesday its phase III trial for experimental therapy, anselamimab, in patients with advanced light chain amyloidosis did not meet its primary endpoint compared to placebo.

The company said the trial's main goal was a hierarchical combination of time to all-cause mortality and frequency of cardiovascular hospitalizations.

Despite missing the primary goal, the company said anselamimab significantly reduced death and hospitalizations in a prespecified patient subgroup.

Light chain amyloidosis is a rare disease characterized by the accumulation of misfolded proteins in organs, particularly the heart and kidneys.

Shares of the company fell nearly 1% to $69.7 in Wednesday's premarket activity.